Human lung adenosquamous carcinoma PD1 antibody acquired drug-resistant primary cell strain and application thereof

• Main Authors: FENG FENGLAN, LI JIN
• Format: Patent
• Language: Chinese; English
• Published: 28.07.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention relates to the technical field of cell biology, in particular to a human lung adenosquamous carcinoma PD1 antibody acquired drug-resistant primary cell strain and application thereof. A PD1 expression positive (35%) adenosquamous carcinoma patient is selected and subjected to four times of neoadjuvant immunotherapy, and after acquired drug resistance is achieved, a drug-resistant part cell model is established. The human lung adenosquamous carcinoma PD1 antibody acquired drug-resistant primary cell strain NSCLC 002T carries TP53 point mutation of a No.4 exon, deletion mutation of a No.3 exon of CDKN2AIP and deletion mutation of a No.39 exon of KMT2D. The cell strain can be used for discussing the anti-tumor drug resistance mechanism of the human lung adenosquamous carcinoma PD1, researching related signal channels of the human lung adenosquamous carcinoma PD1, screening and evaluating anti-tumor immunotherapy drugs, developing tumor immunotherapy drug resistance reversing drugs and the like. 本发明